Results 21 to 30 of about 21,836 (300)

Echinocandin Resistance in Candida [PDF]

Clinical Infectious Diseases, 2015
Invasive fungal infections are an important infection concern for patients with underlying immunosuppression. Antifungal therapy is a critical component of patient care, but therapeutic choices are limited due to few drug classes. Antifungal resistance, especially among Candida species, aggravates the problem.
David S. Perlin
openalex   +4 more sources

Echinocandins – structure, mechanism of action and use in antifungal therapy

Journal of Enzyme Inhibition and Medicinal Chemistry, 2022
With increasing number of immunocompromised patients as well as drug resistance in fungi, the risk of fatal fungal infections in humans increases as well.
Mateusz Szymański, Sandra Chmielewska, U. Czyżewska, M. Malinowska, A. Tylicki   +4 more
semanticscholar   +1 more source

Echinocandins Localized to the Target-Harboring Cell Surface Are Not Degraded but Those Entering the Vacuole Are

ACS Chemical Biology, 2022
Echinocandin antifungal drugs have a broad spectrum of activities and excellent safety profiles. These agents noncompetitively inhibit the formation of the major polysaccharide component of the fungal cell wall, a reaction catalyzed by the membrane-bound
Qais Z. Jaber, Dana Logviniuk, Adi Yona, M. Fridman   +3 more
semanticscholar   +1 more source

In Vitro Synergistic Interactions of Isavuconazole and Echinocandins against Candida auris

Antibiotics, 2021
Candida auris is an emergent fungal pathogen that causes severe infectious outbreaks globally. The public health concern when dealing with this pathogen is mainly due to reduced susceptibility to current antifungal drugs.
Unai Caballero, Sarah Kim, E. Eraso, G. Quindós, Valvanera Vozmediano, S. Schmidt, N. Jauregizar   +6 more
semanticscholar   +1 more source

New strategic insights into managing fungal biofilms [PDF]

, 2015
Fungal infections have dramatically increased in the last decades in parallel with an increase of populations with impaired immunity, resulting from medical conditions such as cancer, transplantation or other chronic diseases.
Borghi, Elisa, Borgo, Francesca, Morace, Giulia, Nile, Christopher, Rajendran, Ranjith, Ramage, Gordon, Sherry, Leighann   +6 more
core   +16 more sources

Hsp90 governs dispersion and drug resistance of fungal biofilms [PDF]

, 2011
Fungal biofilms are a major cause of human mortality and are recalcitrant to most treatments due to intrinsic drug resistance. These complex communities of multiple cell types form on indwelling medical devices and their eradication often requires ...
A Lupetti, A Viudes, C d'Enfert, CA Kumamoto, CJ Nobile, CJ Nobile, D Andes, D Shahinas, David Andes, E Mowat, EM Kojic, ET Burt, G Ramage, G Ramage, G Ramage, G Ramage, G Ramage, Gordon Ramage, J McCourtie, J Nett, J Trepel, JB Anderson, JC Young, JE Nett, Jeniel Nett, Jose L. Lopez-Ribot, JR Blankenship, JS Finkel, L Ostrosky-Zeichner, LE Cowen, LE Cowen, LE Cowen, LE Cowen, LE Cowen, Leah E. Cowen, LH Pearl, LS Wilson, M Taipale, MA Pfaller, MA Pfaller, MJ Seidler, ML Richard, MM McNeil, Nicole Robbins, P Perumal, P Uppuluri, P Uppuluri, P Uppuluri, P Uppuluri, P Uppuluri, PK Mukherjee, Priya Uppuluri, R Pallavi, Ranjith Rajendran, Robin Charles May, RS Shapiro, RS Shapiro, S Garcia-Sanchez, S Park, S Perea, SD Singh, SJ Lin, SL LaFayette, SM Noble, SV Balashov, SZ Usmani, TE Zaoutis, Y Kaneko, YS Kim, Z Odabasi   +69 more
core   +9 more sources

Resistance to Echinocandins Complicates a Case of Candida albicans Bloodstream Infection: A Case Report

Journal of Fungi, 2021
Invasive candidiasis is known to be one of the most common healthcare-associated complications and is caused by several Candida species. First-line drugs, particularly echinocandins, are effective, but there are increasing reports of resistance to these ...
L. Trovato, D. Bongiorno, Maddalena Calvo, Giuseppe Migliorisi, Albino Boraccino, N. Musso, S. Oliveri, S. Stefani, G. Scalia   +8 more
semanticscholar   +1 more source

Pharmacokinetics and Antifungal Activity of Echinocandins in Ascites Fluid of Critically Ill Patients

Antimicrobial Agents and Chemotherapy, 2021
The pharmacokinetics and antifungal activity of the echinocandins anidulafungin (AFG), micafungin (MFG), and caspofungin (CAS) were assessed in ascites fluid and plasma of critically ill adults treated for suspected or proven invasive candidiasis ...
R. Welte, H. Oberacher, Tiziana Gasperetti, H. Pfisterer, A. Griesmacher, Tobias Santner, C. Lass‐Flörl, Caroline Hörtnagl, S. Leitner-Rupprich, M. Aigner, I. Lorenz, S. Schmid, M. Edlinger, P. Eller, D. Dankl, M. Joannidis, R. Bellmann   +16 more
semanticscholar   +1 more source

Micafungin: A New Echinocandin [PDF]

Clinical Infectious Diseases, 2006
Micafungin, a potent inhibitor of 1,3-beta-D-glucan synthase, has become the second available agent in the echinocandins class that is approved for use in clinical practice. This agent shares with caspofungin an identical spectrum of in vitro activity against Candida albicans, non-albicans species of Candida, and Aspergillus species, as well as several
Jack D. Sobel, Pranatharthi H. Chandrasekar   +1 more
openaire   +3 more sources

FKS1 Is Required for Cryptococcus neoformans Fitness In Vivo: Application of Copper-Regulated Gene Expression to Mouse Models of Cryptococcosis

mSphere, 2022
There is an urgent need for new antifungals to treat cryptococcal meningoencephalitis, a leading cause of mortality in people living with HIV/AIDS. An important aspect of antifungal drug development is the validation of targets to determine whether they ...
Sarah R. Beattie, Andrew J. Jezewski, Laura C. Ristow, Melanie Wellington, Damian J. Krysan   +4 more
doaj   +1 more source